产品再次扩列,HPV疫苗市场的多维突围竞争

21世纪经济报道
06 Jun

2025年开年以来,HPV疫苗市场频传重磅消息,默沙东在HPV疫苗市场尤其是男性市场的地位逐渐巩固。2025年4月,默沙东宣布其九价HPV疫苗(酿酒酵母)多项新适应证已获得国家药品监督管理局的上市批准,适用于16~26岁男性接种,这一获批使佳达修®9成为中国境内首个且目前唯一获批、可适用于适龄男性女性接种的九价HPV疫苗。这份捷报背后的企业,是始终秉承拯救生命、改善生活这一使命并深耕疫苗领域...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10